By Doug Macron

Regulus Therapeutics, the microRNA drug joint venture of Alnylam Pharmaceuticals and Isis Pharmaceuticals, announced this week that it has forged a drug-development alliance with Sanofi-Aventis potentially worth more than $750 million.

The deal gives Sanofi-Aventis the rights to develop and sell four therapeutics based on Regulus' technology, including its program in fibrosis. It also adds another notch to the miRNA shop's partnership belt, following a pair of deals inked with GlaxoSmithKline.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcripts, and more.

While James Watson and Francis Crick are credited for discovering the structure of DNA, Rich proved their theory of a double helix structure was correct when he produced a distinct image of the structure.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

According to MIT Technology Review, Apple is collaborating with researchers to develop apps for consumer DNA testing.